Loading…
Genomic diagnostics company making tests that predict recurrence risk for skin cancers and other dermatologic and eye conditions.
Genomic diagnostics company making tests that predict recurrence risk for skin cancers and other dermatologic and eye conditions.
Is paid per test by Medicare and private insurers rather than by the doctors who order them, so coverage decisions and the share of claims actually reimbursed matter as much as test volume. The melanoma and skin-cancer tests carry the business, with newer tests in other conditions still being established.
Moat: narrow (IP / patents, data). Proprietary gene-expression tests built on clinical outcome data guide treatment decisions, hard to replicate quickly.
Headquarters: Friendswood, Texas · Founded: 2007 · Employees: 883
Size Castle Biosciences (CSTL) is a United States Health Care company (Medical Specialties) with a market value of $993M, the 2248th largest of 3,117 United States companies the cockpit tracks. Shares closed at $32.52 on 6 Nov 2026.
Performance Over six months the shares gained 64.0%, against -19.2% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 3.2% over the last twelve months (peer median +10.2%); the operating margin is -9.0% (peer median 11.7%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 4.9× (3rd cheapest of 21).
Capital Return on invested capital runs 20.3 points below its cost of capital (9.7% WACC).
Short interest Short interest is 6.6% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $357M | $344M | $332M | $220M | $137M |
| Revenue growth | — | +4% | +51% | +60% | — |
| Gross profit | $265M | $236M | $259M | $164M | $95.4M |
| EBITDA | -$16.5M | -$2.04M | $24.7M | -$55.6M | -$80.6M |
| Net income | -$19.4M | -$24.2M | $18.2M | -$57.5M | -$67.1M |
| Free cash flow | -$489,000 | $28.3M | $43.2M | -$13.8M | -$45.9M |
| Capital expenditure | $43.1M | $36.0M | $28.3M | $13.6M | $5.63M |
| Total debt | $36.6M | $37.0M | $26.4M | $15.3M | $13.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Castle Biosciences CSTL | $993M | +64% | +3% | -9% | 2.1× | n/a |
| Myriad Genetics MYGN | $566M | +38% | -3% | -11% | 0.8× | n/a |
| Veracyte VCYT | $1.94B | -40% | +17% | 17% | 2.9× | 15.1% |
| Natera NTRA | $44.8B | +60% | +38% | -11% | 16.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CSTL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.5% | -1.8% | 11th highest of 21 |
| 6-month return | +64.0% | -19.2% | highest of 21 |
| Distance from 52-week high | -26.6% | -41.3% | 4th highest of 21 |
| Revenue growth (TTM) | +3.2% | +10.2% | 7th lowest of 21 |
| Operating margin | -9.0% | 11.7% | 4th lowest of 21 |
| EV / Sales | 2.1× | 4.9× | 3rd cheapest of 21 |
| ROIC minus cost of capital | -20.3 pp | -0.9 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 15.6× | 40.1% | +12.4% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 8.0× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 2.5× | 7.2% | +12.1% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | 11.7× | n/a | n/a |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | 8.6× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 5.6× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 3.4× | 3.1% | +12.7% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 1.6× | 5.2% | +3.6% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | 13.5× | 13.1% | +4.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 2.7× | 7.7% | -2.9% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 10.3× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 12.8× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 4.2× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 1.6× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | 9.6× | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 4.0× | 13.3% | +15.5% |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 3.4× | 12.4% | +12.9% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | 26.9× | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 3.5× | 18.0% | +2.9% |